The drug Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP1-R) agonist used for the treatment of T2DM and obesity [110]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.